NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

  • STATUS
    Recruiting
  • End date
    Dec 1, 2023
  • participants needed
    3
  • sponsor
    Fudan University
Send
Updated on 30 November 2021
See if I qualify
metastasis
liver metastasis
blood transfusion

Summary

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

Description

The preclinical study clarified that NKG2D-based CAR-T cells showed strong cytotoxicity against NKG2DL+ cell lines in vitro as well as a therapeutic effect against NKG2DL+ cell xenografts in vivo. In addition, the data also demonstrated the safety of NKG2D-based CAR-T therapy. NKG2D-based CART represent a potentially effective and safety therapeutic approach for patient with relapsed/refractory NKG2DL+ solid tumors. In this trial, the investigators researched the safety of administering NKG2D-based CAR-T which generated with CD8 hinge region and transmembrane region, 4-1BB costimulatory region and CD3 zeta region. The investigators also assessed that disease response was determined within the context of a phase I trial.

Details
Condition Colon Cancer, Gliomas, HEPATIC NEOPLASM, Liver Cancer, Malignant Adenoma, Medulloblastoma, colon carcinoma, liver cell carcinoma, Colorectal Cancer, Colon Cancer Screening, Glioma, glioblastoma, Colon cancer; rectal cancer, HEPATOCELLULAR CARCINOMA, Adenocarcinoma, Malignant neoplasm of colon, Glioblastoma multiforme, Glioblastoma Multiforme
Treatment NKG2D-based CAR T-cells
Clinical Study IdentifierNCT05131763
SponsorFudan University
Last Modified on30 November 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Men or women18 years old
Patient with NKG2DL+ cell tumors confirmed by pathology and histology
Fail or unwilling to receive first-line treatment
Disease must be measurable according to the corresponding guidelines
Main organs function normally and meet following requirements
Routine blood index No Blood transfusion within 14 days 1)HB90g/ L
)ANC1.5109/L; 3)PLT75109/L# Serum biochemicals index 1) BIL <1.5 upper normal
limit (ULN); 2) ALT and AST<2.5ULN; In the case of liver metastasis, ALT and
AST<5ULN; 3) Serum Cr1ULN, endogenous creatinine clearance50ml/min (Cockcroft-
Gault formula); 4) ECOG physical condition score: 0-2
\. Expected survival time 3 months
\. Patient with adequate bone marrow reserve, hepatic and renal functions
\. No other uncontrolled diseases such as lung, kidney and liver infection
before enrollment
\. Women of child-bearing age must undergo a negative pregnancy test (serum
or urine) within 7 days prior to enrollment and voluntarily use appropriate
methods of contraception during the observation period and within 8 weeks
after the last dose; men should agree to contraception during the observation
period and within 8 weeks of the last dose
\. Patients voluntarily participated in this trial and sign the informed
consent form
\. Patients with compliance and expected to follow up the efficacy and
adverse reactions as required by the protocol

Exclusion Criteria

\. Pregnant or lactating women, 2. Patients who need to use systemic steroids at the same time, 3. Under following treatment conditions currently: 1) during the other antitumor clinical observation period within 14 days before blood collection; 2) patient has not recovered from acute side effects of the previous treatment; 4. Receive radiotherapy within 4 weeks before enrollment, 5. Patients who received any other cell therapy before, 6. Patients with unqualified T cell amplification efficiency, 7. Uncontrolled symptoms or other illnesses, including but not limited to infection, congestive heart failure, unstable angina, arrhythmia, psychosis, 8. Patients with severe acute allergic reactions, 9. Patients who have received other cell therapies, 10. Other serious conditions that may limit patient's participation in the study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

metastasis
liver metastasis
blood transfusion

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note